Why Some AML Patients Develop Resistance to Tagraxofusp
Patients with acute myeloid leukemia (AML) develop resistance to tagraxofusp when leukemia cells stop expressing the CD123 receptor, according to research published in Blood. This “antigen loss” prevents the drug from identifying and attacking the cancer cells, rendering the targeted therapy ineffective despite the drug’s presence in the system.
How does tagraxofusp target leukemia cells?
Tagraxofusp is a targeted therapy designed specifically for AML patients with a high expression of CD123, a protein found on the surface of leukemia blasts. According to the U.S. Food and Drug Administration (FDA), the drug acts as a “cytokine conjugate.” It combines a targeting moiety that binds to CD123 with a potent toxin (cytochrome 2C9) that kills the cell from the inside.
For the drug to work, the CD123 receptor must be present on the cell surface. If the receptor is missing or mutated, the drug cannot attach to the cell, and the toxin cannot be delivered into the leukemia blast.
Why do patients develop resistance to the drug?
Resistance typically occurs through a process called clonal evolution. Research indicates that while tagraxofusp successfully kills CD123-positive cells, it creates a selective pressure. This environment allows a small population of CD123-negative cells—which may have existed in tiny numbers before treatment—to survive and multiply.
According to the study published in Blood, this results in “antigen escape.” The leukemia essentially evolves to hide the target the drug is looking for. Because the drug no longer recognizes the cells, the cancer resumes growth, often appearing as a relapse that is no longer responsive to the same medication.
How does this compare to other AML treatments?
The mechanism of resistance in tagraxofusp differs from traditional chemotherapy, which typically fails due to DNA repair mechanisms or efflux pumps that push the drug out of the cell. Tagraxofusp resistance is a structural failure of recognition.
| Feature | Traditional Chemotherapy | Tagraxofusp (Targeted) |
|---|---|---|
| Target | Rapidly dividing cells (General) | CD123 Protein (Specific) |
| Resistance Cause | Drug efflux/DNA repair | Antigen loss (CD123 disappearance) |
| Selectivity | Low (affects healthy cells) | High (targets leukemia blasts) |
What are the implications for future AML treatment?
The discovery of CD123 loss suggests that doctors may need to monitor antigen expression throughout the course of treatment, rather than just at the start. If a physician can detect the emergence of CD123-negative clones early via bone marrow biopsies, they can switch therapies before a full clinical relapse occurs.
Researchers are now exploring “combination therapies” to prevent this escape. By pairing tagraxofusp with other agents that target different proteins on the leukemia cell, clinicians hope to kill both the CD123-positive and CD123-negative populations simultaneously, leaving the cancer with no path to evolve.
Frequently Asked Questions
Does everyone with AML develop this resistance?
No. Resistance depends on the genetic makeup of the patient’s leukemia. Only patients who start with a population of cells that can evolve to lose CD123 expression face this specific type of resistance.
Can the drug be “restarted” once resistance happens?
Generally, no. Once the leukemia cells have evolved to be CD123-negative, tagraxofusp cannot bind to them. Treatment usually requires a shift to a different class of medication or a stem cell transplant.
Is tagraxofusp approved for all AML patients?
No. It is typically indicated for adult patients with relapsed or refractory AML who have inadequate options for therapy, specifically those showing high levels of CD123 expression.